Literature DB >> 21063760

Changes in regional brain volumes in social anxiety disorder following 12 weeks of treatment with escitalopram.

Naseema Cassimjee1, Jean-Pierre Fouche, Michael Burnett, Christine Lochner, James Warwick, Patrick Dupont, Dan J Stein, Karen J Cloete, Paul D Carey.   

Abstract

It has been suggested that antidepressants, including the selective serotonin reuptake inhibitors have neurotrophic effects. Nevertheless, the impact of treatment with a selective serotonin re-uptake inhibitor on regional brain volumes in social anxiety disorder has not been studied. 11 subjects with social anxiety disorder completed magnetic resonance imaging both before and after 12-weeks of treatment with 20 mg/day escitalopram. No increases in structural grey matter were found, but there were decreases in bilateral superior temporal cortex, vermis and the left cerebellum volumes following 12 weeks of treatment with escitalopram. These preliminary findings require replication to determine their reliability, and extension to determine whether or not they are disorder specific.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063760     DOI: 10.1007/s11011-010-9218-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  32 in total

1.  Neural correlates of speech anticipatory anxiety in generalized social phobia.

Authors:  Jeffrey P Lorberbaum; Samet Kose; Michael R Johnson; George W Arana; Lindsay K Sullivan; Mark B Hamner; James C Ballenger; R Bruce Lydiard; Peter S Brodrick; Daryl E Bohning; Mark S George
Journal:  Neuroreport       Date:  2004-12-22       Impact factor: 1.837

2.  Social phobia.

Authors:  M R Liebowitz
Journal:  Mod Probl Pharmacopsychiatry       Date:  1987

3.  A voxel-based morphometric study of ageing in 465 normal adult human brains.

Authors:  C D Good; I S Johnsrude; J Ashburner; R N Henson; K J Friston; R S Frackowiak
Journal:  Neuroimage       Date:  2001-07       Impact factor: 6.556

4.  A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder.

Authors:  J M Warwick; P Carey; G Van der Linden; C Prinsloo; D Niehaus; S Seedat; P Dupont; D J Stein
Journal:  Metab Brain Dis       Date:  2006-07-19       Impact factor: 3.584

5.  Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.

Authors:  G Chételat; B Landeau; F Eustache; F Mézenge; F Viader; V de la Sayette; B Desgranges; J-C Baron
Journal:  Neuroimage       Date:  2005-10-01       Impact factor: 6.556

Review 6.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

7.  A cerebellar-vestibular explanation for fears/phobias: hypothesis and study.

Authors:  H N Levinson
Journal:  Percept Mot Skills       Date:  1989-02

8.  The cerebellar-vestibular predisposition to anxiety disorders.

Authors:  H N Levinson
Journal:  Percept Mot Skills       Date:  1989-02

9.  The neural correlates of social anxiety disorder and response to pharmacotherapy.

Authors:  Clinton D Kilts; Jeffrey E Kelsey; Bettina Knight; Timothy D Ely; F DuBois Bowman; Robin E Gross; Amy Selvig; Angelita Gordon; D Jeffrey Newport; Charles B Nemeroff
Journal:  Neuropsychopharmacology       Date:  2006-03-08       Impact factor: 7.853

10.  Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment.

Authors:  Chi-Hua Chen; Khanum Ridler; John Suckling; Steve Williams; Cynthia H Y Fu; Emilio Merlo-Pich; Ed Bullmore
Journal:  Biol Psychiatry       Date:  2007-01-09       Impact factor: 13.382

View more
  7 in total

1.  Pattern of structural brain changes in social anxiety disorder after cognitive behavioral group therapy: a longitudinal multimodal MRI study.

Authors:  V R Steiger; A B Brühl; S Weidt; A Delsignore; M Rufer; L Jäncke; U Herwig; J Hänggi
Journal:  Mol Psychiatry       Date:  2016-12-06       Impact factor: 15.992

2.  Gray matter abnormalities in social anxiety disorder: primary, replication, and specificity studies.

Authors:  Ardesheer Talati; Spiro P Pantazatos; Franklin R Schneier; Myrna M Weissman; Joy Hirsch
Journal:  Biol Psychiatry       Date:  2012-06-29       Impact factor: 13.382

3.  A pilot study of gray matter volume changes associated with paroxetine treatment and response in social anxiety disorder.

Authors:  Ardesheer Talati; Spiro P Pantazatos; Joy Hirsch; Franklin Schneier
Journal:  Psychiatry Res       Date:  2015-01-19       Impact factor: 3.222

4.  The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls.

Authors:  R Seiger; G Gryglewski; M Klöbl; A Kautzky; G M Godbersen; L Rischka; T Vanicek; M Hienert; J Unterholzner; L R Silberbauer; P Michenthaler; P Handschuh; A Hahn; S Kasper; R Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

5.  Neuroplasticity in response to cognitive behavior therapy for social anxiety disorder.

Authors:  K N T Månsson; A Salami; A Frick; P Carlbring; G Andersson; T Furmark; C-J Boraxbekk
Journal:  Transl Psychiatry       Date:  2016-02-02       Impact factor: 6.222

6.  Dissociations in cortical thickness and surface area in non-comorbid never-treated patients with social anxiety disorder.

Authors:  Xun Zhang; Qiang Luo; Song Wang; Lihua Qiu; Nanfang Pan; Weihong Kuang; Su Lui; Xiaoqi Huang; Xun Yang; Graham J Kemp; Qiyong Gong
Journal:  EBioMedicine       Date:  2020-07-30       Impact factor: 8.143

Review 7.  Gray Matter Structural Alterations in Social Anxiety Disorder: A Voxel-Based Meta-Analysis.

Authors:  Xiuli Wang; Bochao Cheng; Qiang Luo; Lihua Qiu; Song Wang
Journal:  Front Psychiatry       Date:  2018-09-21       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.